Engineered Mut PIK3CA–specific TCR-T cells showed an antitumor response against established tumors in vivo in mice bearing PIK3CA-Mut tumor but not wild-type PIK3CA tumors (36). This evidence concerns the gene PIK3CA and neoplasm.